Abstract：Objective To evaluate the effect of Montelukast assisted Azithromycin in the treatment of pediatric asthmatic bronchitis.Methods A total of 120 children with asthmatic bronchitis treated in our hospital from January 2016 to October 2017 were selected as subjects and divided into the single drug group and combination group according to random number table method,60 in each group.The single drug group were given Azithromycin alone and the combination group was treated with Montelukast Sodium assisted Azithromycin.The therapeutic effect,symptom relief time,the index of hypersensitive C-reactive protein (hsCRP)and the incidence of adverse reactions of two groups were compared.Results After treatment,the total effective rate of the children in the combination group (95.00%)was higher than that of the single drug group(78.33%),and the difference was statistically significant(P＜0.05).The relief time of cough,wheezing,wheezing sound,the temperature dropped to the normal range and hospitalization days of the children in the combination group were significantly shorter than those in the single drug group,and the differences were statistically significant(P＜0.05).After treatment,two groups of children with hypersensitive C-reactive protein levels were lower than before treatment,and combination group with hypersensitive C-reactive protein levels were lower than that in the single drug groups,the differences were statistically significant(P＜0.05).The incidence of adverse reactions of the children in the combination group(3.33%)was lower than that of the single drug group(18.33%),and the difference was statistically significant(P＜0.05).Conclusion Montelukast Sodium is a good adjuvant for the treatment of asthmatic bronchitis,it can improve the clinical efficacy.The improvement of various symptoms is rapid,and the incidence of adverse reactions low,with safety and reliability.
京公网安备 11010502046607号